Pure Global AI
NCT05805501Recruiting

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La RochePhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Drug/Device/Intervention
RO7247669
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hoffmann-La Roche
Location
Fort Myers,Chattanooga,Knoxville,Nashville,Birtinya,Kurralta Park,Beijing City,Beijing,Nanjing City,Tianjin,Xi'an,Bordeaux,Caen,Lyon,Goyang-si,Jeollanam-do,Seoul,Seoul,Seoul,Bydgoszcz,Kraków,Pozna?,Ma, Australia,China,France,Poland,South Korea,Spain,United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Apr 21, 2023
End date
Mar 31, 2026
Enrollment
210 participants
Primary outcome

Progression-Free Survival (PFS)

Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of RO7247669 (PD1-LAG3)
 in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared
 to pembrolizumab and axitinib in participants with previously untreated, unresectable locally
 advanced or metastatic clear-cell renal cell carcinoma (ccRCC).

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05805501
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05805501 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hoffmann-La Roche and is currently Recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 210 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.